In Situ, Autologous Therapeutic Vaccination Against Solid Cancers with Intratumoral Hiltonol® (Poly-ICLC)

ID Number 13-1687

Principal Investigator(s)
Nina Bhardwaj

Department(s) or Division(s)
Hematology and Medical Oncology


This study will test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle.  

Poly-ICLC is a compound that has been used to help the body in its fight against cancer.

Subjects may qualify if they have melanoma, non-melanoma skin cancer, head and neck cancer, sarcoma, or breast cancer.

Contact Information

Recruiting Patients: Yes